Medical Policy
Endothelial Keratoplasty

Table of Contents
• Policy: Commercial
• Coding Information
• Information Pertaining to All Policies
• Policy: Medicare
• Description
• References
• Authorization Information
• Policy History

Policy Number: 180
BCBSA Reference Number: 9.03.22
NCD/LCD: N/A

Related Policies
• Keratoprosthesis, #221
• Optical Coherence Tomography of the Anterior Eye Segment, #084

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Endothelial keratoplasty [Descemet’s stripping endothelial keratoplasty (DSEK) Descemet’s stripping automated endothelial keratoplasty (DSAEK)], Descemet’s membrane endothelial keratoplasty [DMEK], or Descemet’s membrane automated endothelial keratoplasty [DMAEK]) may be considered MEDICALLY NECESSARY for the treatment of endothelial dysfunction, including but not limited to:

- Ruptures in Descemet’s membrane,
- Endothelial dystrophy,
- Aphakic and pseudophakic bullous keratopathy,
- Iridocorneal endothelial (ICE) syndrome,
- Corneal edema attributed to endothelial failure, or
- Failure or rejection of a previous corneal transplant.

Femtosecond laser-assisted corneal endothelial keratoplasty (FLEK) or femtosecond and excimer lasers-assisted endothelial keratoplasty (FELEK) are INVESTIGATIONAL.

Endothelial keratoplasty is NOT MEDICALLY NECESSARY when endothelial dysfunction is not the primary cause of decreased corneal clarity.

Prior Authorization Information
Inpatient
• For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

**Outpatient**

• For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

<table>
<thead>
<tr>
<th></th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
<tr>
<td>Medicare HMO BlueSM</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
<tr>
<td>Medicare PPO BlueSM</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
</tbody>
</table>

**CPT Codes / HCPCS Codes / ICD Codes**

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

The above **medical necessity criteria** MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

**CPT Codes**

<table>
<thead>
<tr>
<th>CPT codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>65756</td>
<td>Keratoplasty (corneal transplant); endothelial</td>
</tr>
<tr>
<td>65757</td>
<td>Backbench preparation of corneal endothelial allograft prior to transplantation (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

The following **ICD Diagnosis Codes** are considered medically necessary when submitted with the CPT codes above if **medical necessity criteria** are met:

**ICD-10 Diagnosis Codes**

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>H18.10</td>
<td>Bullous keratopathy, unspecified eye</td>
</tr>
<tr>
<td>H18.11</td>
<td>Bullous keratopathy, right eye</td>
</tr>
<tr>
<td>H18.12</td>
<td>Bullous keratopathy, left eye</td>
</tr>
<tr>
<td>H18.13</td>
<td>Bullous keratopathy, bilateral</td>
</tr>
<tr>
<td>H18.20</td>
<td>Unspecified corneal edema</td>
</tr>
<tr>
<td>H18.211</td>
<td>Corneal edema secondary to contact lens, right eye</td>
</tr>
<tr>
<td>H18.212</td>
<td>Corneal edema secondary to contact lens, left eye</td>
</tr>
<tr>
<td>H18.213</td>
<td>Corneal edema secondary to contact lens, bilateral</td>
</tr>
<tr>
<td>H18.219</td>
<td>Corneal edema secondary to contact lens, unspecified eye</td>
</tr>
<tr>
<td>H18.221</td>
<td>Idiopathic corneal edema, right eye</td>
</tr>
<tr>
<td>H18.222</td>
<td>Idiopathic corneal edema, left eye</td>
</tr>
<tr>
<td>H18.223</td>
<td>Idiopathic corneal edema, bilateral</td>
</tr>
<tr>
<td>H18.229</td>
<td>Idiopathic corneal edema, unspecified eye</td>
</tr>
</tbody>
</table>
### Description

**Corneal Disease**

The cornea, a clear, dome-shaped membrane that covers the front of the eye, is a key refractive element for vision. Layers of the cornea consist of the epithelium (outermost layer); Bowman layer; the stroma, which comprises approximately 90% of the cornea; Descemet membrane; and the endothelium. The endothelium removes fluid from and limits fluid into the stroma, thereby maintaining the ordered arrangement of collagen and preserving the cornea’s transparency. Diseases that affect the endothelial layer include Fuchs endothelial dystrophy, aphakic and pseudophakic bullous keratopathy (corneal edema following cataract extraction), and failure or rejection of a previous corneal transplant.

**Treatment**

The established surgical treatment for corneal disease is penetrating keratoplasty, which involves the creation of a large central opening through the cornea and then filling the opening with full-thickness donor cornea that is sutured in place. Visual recovery after penetrating keratoplasty may take 1 year or more due to slow wound healing of the avascular full-thickness incision, and the procedure frequently results in irregular astigmatism due to sutures and the full-thickness vertical corneal wound. Penetrating keratoplasty is associated with an increased risk of wound dehiscence, endophthalmitis, and total visual loss after relatively minor trauma for years after the index procedure. There is also the risk of severe, sight-threatening complications such as expulsive suprachoroidal hemorrhage, in which the ocular contents are expelled during the operative procedure, as well as postoperative catastrophic wound failure.

A number of related techniques have been, or are being, developed to selectively replace the diseased endothelial layer. One of the first endothelial keratoplasty techniques was termed *deep lamellar endothelial keratoplasty*, which used a smaller incision than penetrating keratoplasty, allowed more rapid
visual rehabilitation, and reduced postoperative irregular astigmatism and suture complications. Modified endothelial keratoplasty techniques include endothelial lamellar keratoplasty, endokeratoplasty, posterior corneal grafting, and microkeratome-assisted posterior keratoplasty. Most frequently used at this time are Descemet stripping endothelial keratoplasty, which uses hand-dissected donor tissue, and Descemet stripping automated endothelial keratoplasty, which uses an automated microkeratome to assist in donor tissue dissection. These techniques include donor stroma along with the endothelium and Descemet membrane, which results in a thickened stromal layer after transplantation. If the donor tissue comprises Descemet membrane and endothelium alone, the technique is known as Descemet membrane endothelial keratoplasty. By eliminating the stroma on the donor tissue and possibly reducing stromal interface haze, Descemet membrane endothelial keratoplasty is considered a potential improvement over Descemet stripping endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty. A variation of Descemet membrane endothelial keratoplasty is Descemet membrane automated endothelial keratoplasty. Descemet membrane automated endothelial keratoplasty contains a stromal rim of tissue at the periphery of the Descemet membrane endothelial keratoplasty graft to improve adherence and improve handling of the donor tissue. A laser may also be used for stripping in a procedure called femtosecond laser-assisted endothelial keratoplasty and femtosecond and excimer laser-assisted endothelial keratoplasty.

Endothelial keratoplasty involves removal of the diseased host endothelium and Descemet membrane with special instruments through a small peripheral incision. A donor tissue button is prepared from the corneoscleral tissue after removing the anterior donor corneal stroma by hand (eg, Descemet stripping endothelial keratoplasty) or with the assistance of an automated microkeratome (eg, Descemet stripping automated endothelial keratoplasty) or laser (femtosecond laser-assisted endothelial keratoplasty or femtosecond and excimer laser-assisted endothelial keratoplasty). Donor tissue preparation may be performed by the surgeon in the operating room or by the eye bank and then transported to the operating room for final punch out of the donor tissue button. For minimal endothelial damage, the donor tissue must be carefully positioned in the anterior chamber. An air bubble is frequently used to center the donor tissue and facilitate adhesion between the stromal side of the donor lenticule and the host posterior corneal stroma. Repositioning of the donor tissue with the application of another air bubble may be required in the first week if the donor tissue dislocates. The small corneal incision is closed with 1 or more sutures, and steroids or immune-suppressants may be provided topically or orally to reduce the potential for graft rejection. Visual recovery following endothelial keratoplasty is typically 4 to 8 weeks.

Eye Bank Association of America statistics have shown the number of endothelial keratoplasty cases in the United States increased from 30,710 in 2015 to 32,221 in 2016. The Eye Bank Association of America estimated that, as of 2016, nearly 40% of corneal transplants performed in the United States were endothelial grafts. As with any new surgical technique, questions have been posed about long-term efficacy and risk of complications. Endothelial keratoplasty-specific complications include graft dislocations, endothelial cell loss, and rate of failed grafts. Long-term complications include increased intraocular pressure, graft rejection, and late endothelial failure.

**Summary**

Endothelial keratoplasty also referred to as posterior lamellar keratoplasty, is a form of corneal transplantation in which the diseased inner layer of the cornea, the endothelium, is replaced with healthy donor tissue. Specific techniques include Descemet stripping endothelial keratoplasty, Descemet stripping automated endothelial keratoplasty, Descemet membrane endothelial keratoplasty, and Descemet membrane automated endothelial keratoplasty. Endothelial keratoplasty, and particularly Descemet stripping endothelial keratoplasty, Descemet stripping automated endothelial keratoplasty, Descemet membrane endothelial keratoplasty, and Descemet membrane automated endothelial keratoplasty, are becoming standard procedures. Femtosecond laser-assisted endothelial keratoplasty and femtosecond and excimer laser-assisted endothelial keratoplasty have also been reported as alternatives to prepare the donor endothelium.

For individuals who have endothelial disease of the cornea who receive Descemet stripping endothelial keratoplasty or Descemet stripping automated endothelial keratoplasty, the evidence includes a number of cohort studies, a randomized controlled trial (RCT), and systematic reviews. Relevant outcomes are
change in disease status, morbid events, and functional outcomes. The available literature has indicated that these procedures improve visual outcomes and reduce serious complications associated with penetrating keratoplasty. Specifically, visual recovery occurs much earlier. Because endothelial keratoplasty maintains an intact globe without a sutured donor cornea, astigmatism or the risk of severe, sight-threatening complications such as expulsive suprachoroidal hemorrhage and postoperative catastrophic wound failure are eliminated. The Descemet Endothelial Thickness Comparison Trial (DETECT) RCT reported improved visual acuity outcomes with Descemet membrane endothelial keratoplasty compared to ultra-thin Descemet stripping automated endothelial keratoplasty. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have endothelial disease of the cornea who receive Descemet membrane endothelial keratoplasty or Descemet membrane automated endothelial keratoplasty, the evidence includes a number of cohort studies and systematic reviews. Relevant outcomes are change in disease status, morbid events, and functional outcomes. Evidence from the cohort studies and meta-analyses has consistently shown that the use of Descemet membrane endothelial keratoplasty and Descemet membrane automated endothelial keratoplasty procedures improve visual acuity. When compared with Descemet stripping endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty, Descemet membrane endothelial keratoplasty and Descemet membrane automated endothelial keratoplasty showed significantly greater improvements in visual acuity, both in the short term and through 1 year of follow-up. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have endothelial disease of the cornea who receive femtosecond laser-assisted endothelial keratoplasty and femtosecond and excimer laser-assisted endothelial keratoplasty, the evidence includes a multicenter RCT comparing femtosecond laser-assisted endothelial keratoplasty with penetrating keratoplasty and an RCT comparing femtosecond-prepared Descemet stripping automated endothelial keratoplasty to microkeratome-prepared Descemet membrane automated endothelial keratoplasty. Relevant outcomes are change in disease status, morbid events, and functional outcomes. Mean best-corrected visual acuity was worse after femtosecond laser-assisted endothelial keratoplasty than after penetrating keratoplasty, and endothelial cell loss was higher with femtosecond laser-assisted endothelial keratoplasty. With the exception of dislocation and need for repositioning of the femtosecond laser-assisted endothelial keratoplasty, the percentage of complications was similar between groups. Complications in the femtosecond laser-assisted endothelial keratoplasty group were due to pupillary block, graft failure, epithelial ingrowth, and elevated intraocular pressure, whereas complications in the penetrating keratoplasty group were related to sutures and elevated intraocular pressure. Worsened visual acuity and a 100% graft dislocation rate was reported for femtosecond-prepared Descemet stripping automated endothelial keratoplasty compared to 0% in manually-prepared Descemet stripping automated endothelial keratoplasty. The evidence is insufficient to determine the effects of the technology on health outcomes.

2013 Input
Clinical input was sought to help determine whether the use of endothelial keratoplasty for individuals with endothelial disease of the cornea would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 3 specialty society-level response(s) and 3 academic medical centers.

For individuals who have endothelial disease of the cornea who receive Descemet membrane endothelial keratoplasty and Descemet membrane automated endothelial keratoplasty, clinical input supports this use provides a clinically meaningful improvement in net health outcome and indicates this use is consistent with generally accepted medical practice.

For individuals who have endothelial disease of the cornea who receive femtosecond laser-assisted endothelial keratoplasty and femtosecond and excimer laser-assisted endothelial keratoplasty, clinical
input does not support a clinically meaningful improvement in net health outcome and does not indicate this use is consistent with generally accepted medical practice.

2009 Input
Clinical input was sought to help determine whether the use of endothelial keratoplasty for individuals with endothelial disease of the cornea would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 3 specialty society-level response(s) and 2 academic medical centers.

For individuals who have endothelial disease of the cornea who receive Descemet stripping endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty, clinical input supports this use provides a clinically meaningful improvement in net health outcome and indicates this use is consistent with generally accepted medical practice.

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/2020</td>
<td>Clarified coding information</td>
</tr>
<tr>
<td>2/2018</td>
<td>Clarified coding information</td>
</tr>
<tr>
<td>10/2017</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>4/2016</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>11/2015</td>
<td>Added coding language.</td>
</tr>
<tr>
<td>5/2014</td>
<td>Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.</td>
</tr>
<tr>
<td>1/2014</td>
<td>Clarified coding information</td>
</tr>
</tbody>
</table>

Information Pertaining to All Blue Cross Blue Shield Medical Policies
Click on any of the following terms to access the relevant information:
Medical Policy Terms of Use
Managed Care Guidelines
Indemnity/PPO Guidelines
Clinical Exception Process
Medical Technology Assessment Guidelines

References


